Journal of Psychosomatic Research
Volume 68, Issue 6 , Pages 573-579 , June 2010

Effect of menopause and use of contraceptives/hormone therapy on association of C-reactive protein and depression: A population-based study

  • Timo Liukkonen

      Affiliations

    • Department of Psychiatry, Savonlinna Central Hospital, Savonlinna, Finland
    • Institute of Health Sciences, University of Oulu, University of Oulu, Finland
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Savonlinna Central Hospital, Keskussairaalantie 6, FIN-57120 Savonlinna, Finland. Tel.: +358 15 581 7015; fax: +358 15 581 7016.
    • ,
  • Mauno Vanhala

      Affiliations

    • Unit of General Practice, Centre Finland Central Hospital, Jyväskylä, Finland
    • Family Practice Unit, Kuopio University and Kuopio University Hospital, Kuopio, Finland
    • ,
  • Jari Jokelainen

      Affiliations

    • Institute of Health Sciences, University of Oulu, University of Oulu, Finland
    • Unit of General Practice, Oulu University Hospital, OYS, Finland
    • ,
  • Sirkka Keinänen-Kiukaanniemi

      Affiliations

    • Institute of Health Sciences, University of Oulu, University of Oulu, Finland
    • Unit of General Practice, Oulu University Hospital, OYS, Finland
    • Oulu Health Centre, City of Oulu, Finland
    • ,
  • Hannu Koponen

      Affiliations

    • Department of Psychiatry, Kuopio University and University Hospital, Kuopio, Finland; and the Academy of Finland
    • ,
  • Markku Timonen

      Affiliations

    • Institute of Health Sciences, University of Oulu, University of Oulu, Finland

Received 2 December 2008 ,Revised 3 November 2009 ,Accepted 3 November 2009.

References 

  1. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiat. 1995;19:11–38
  2. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med. 2003;65:347–356
  3. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004;164:1010–1014
  4. Liukkonen T, Silvennoinen-Kassinen S, Jokelainen J, Räsänen P, Leinonen M, Meyer-Rochow VB, et al. The association between C-reactive protein (CRP) levels and depression: results from the Northern Finland 1966 Birth Cohort study. Biol Psychiatry. 2006;60:825–830
  5. Ladwig K-H, Marten-Mittag B, Löwel H, Döring A, Koenig W. Influence of depressive mood on the association of CRP and obesity in 3205 middle aged healthy men. Brain Behav Immun. 2003;17:268–275
  6. Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J, et al. Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol. 2002;89:419–424
  7. Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S, et al. Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol Psychiatry. 2003;54:566–572
  8. Pikhart H, Hubacek JA, Kubinova R, Nicholson A, Peasey A, Capkova N, et al. Depressive symptoms and levels of C-reactive protein: a population-based study. Soc Psychiatry Psychiatr Epidemiol. 2008;[Epub ahead of print]
  9. Elovainio M, Keltikangas-Järvinen L, Pulkki-Råback L, Kivimäki M, Puttonen S, Räsänen L, et al. Depressive symptoms and C-reactive protein: the cardiovascular risk in young Finns study. Psychol Med. 2006;36:797–805
  10. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psych. 2005;58:175–189
  11. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet. 2005;365:610–612
  12. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571
  13. Vanhala MJ, Kumpusalo EA, Pitkajarvi TK, Takala JK. Metabolic syndrome in a middle-aged Finnish population. J Cardiovasc Risk. 1997;4:291–295
  14. Luoto R, Kaprio J, Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol. 1994;139:64–76
  15. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7:151–169
  16. Honkalampi K, Hintikka J, Tanskanen A, Lehtonen J, Viinamaki . Depression is strongly associated with alexithymia in the general population. J Psychosomatic Res. 2000;48:99–104
  17. Pesonen A-K, Räikkonen K, Heinonen K, Kajantie E, Forse'n T, Eriksson JG. Depressive symptoms in adults separated from their parents as children: a natural experiment during World War II. Am J Epidemiol. 2007;166:1126–1133
  18. Aziz N, Fahey JL, Detels R, Butch AW. Analytic performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diagn Lab Immunol. 2003;4:652–657
  19. Picardi A, Valorani MG, Vespasiani Gentilucci U. Raised C-reactive protein levels in patients with recent onset type 1 diabetes. Diabetes Metab Res Rev. 2006;23:211–214
  20. Koenig W, Sund M, Fröchlich M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–242
  21. Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  22. Lespérance F, Nancy Frasure-Smith N, Théroux P, Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry. 2004;161:271–277
  23. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol. 2006;97:33A–41A
  24. Roberts RE, Kaplan GA, Shema SJ, Strawbridge WJ. Are the obese at greater risk for depression?. Am Epidemiol. 2000;152:163–170
  25. Breslau N, Kilbey MM, Andreski P. Nicotine dependence and major depression. New evidence from a prospective investigation. Arch Gen Psychiatry. 1993;50:31–35
  26. Goodwin RD. Association between physical activity and mental disorders among adults in the United States. Prev Med. 2003;36:698–703
  27. Roy A, DeJong J, Lamparski D, George T, Linnoila M. Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry. 1991;48:428–432
  28. Lehtinen V, Joukamaa M. Epidemiology of depression: prevalence, risk factors and treatment situation. Acta Psychiatr Scand. 1994;377:7–10
  29. Katon WJ, Lin EH, Russo J. Cardiac risk factors in patients with diabetes mellitus and major depression. J Gen Intern Med. 2004;19:1192–1199
  30. Williams MJA, Williams SM, Milne BJ, Hancox RJ, Poulton R. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes. 2004;28:998–1003
  31. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399–403
  32. Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler MM. Inflammatory proteins and depression in the elderly. Epidemiology. 2003;14:103–107
  33. Steptoe A, Kunz-Ebrecht SR, Owen N. Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. Psychol Med. 2003;33:667–674
  34. Matthews KA, Schott LL, Bromberger J, Cyranowski J, Everson-Rose SA, Sowers MF. Associations between depressive symptoms and inflammatory/hemostatic markers in women during the menopausal transition. Psychol Med. 2007;69:124–130
  35. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–1811
  36. Hulley S, Grady D, Bush T, Fulberg C, Herrington D, Riggs B, et al. Heart and estrogen/progestin replacement study (HERS). Research group. JAMA. 1998;280:605–613
  37. Writing Group for the Women's health Initiative Investigators. Risk and benefits of estrogen in postmenopausal women. JAMA. 2002;288:321–333
  38. Maturana MA, Irigoyen MC, Spitzer PM. Menopause, estrogens, and endothelial dysfunction: current concepts. Clinics. 2007;62:77–86
  39. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477
  40. Das UN. Vagus nerve stimulation, depression, and inflammation. Neuropsychopharmacology. 2007;32:2053–2054
  41. Shiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29:201–217
  42. Dantzer R, O'Connor JO, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev. 2008;9:46–57
  43. Van den Biggelaar AH, Gussekloo J, de Craen AJ, Frölich M, Stek ML, Van der Mast RC, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol. 2007;42:693–701
  44. Gimeno D, Kivimäki M, Brunner EJ, Elovainio R, De Vogli R, Steptoe A, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2008;1–11[Epub ahead of print]
  45. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63:375–382
  46. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition. The Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006;63:385–390
  47. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affect Disord. 2003;74:67–83
  48. Shors TJ, Leuner B. Estrogen-mediated effects on depression and memory formation in females. J Affect Disord. 2003;74:85–96
  49. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31:464–468
  50. Pariante CM, Miller AH. Glucocorticoid receptor in major depression: relevance to the pathophysiology and treatment. Biol Psychiatry. 2001;49:391–404
  51. De Nicole AF, Saravia FE, Beauguis J, Pietranere L, Ferrini MG. Estrogenes and neuroendocrine hypothalamic–pituitary–adrenal axis function. Front Horm Res. 2006;35:157–168
  52. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbances: where is the therapeutic bridge?. Biol Psychiatry. 1998;44:798–811
  53. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20:279–307
  54. Aloysi A, Van Dyk K, Sano M. Women's cognitive and affective health and neuropsychiatry. Mt Sinai J Med. 2006;73:967–975
  55. Lee KC, Ray GT, Hunkeler EM, Finley PR. Tamoxifen treatment and new-onset depression in breast cancer patients. Psychosomatics. 2007;48:205–210

PII: S0022-3999(09)00461-9

doi: 10.1016/j.jpsychores.2009.11.003

Journal of Psychosomatic Research
Volume 68, Issue 6 , Pages 573-579 , June 2010

Article Tools

* Image Usage & Resolution